170P EO2401 microbiome derived therapeutic vaccine + nivolumab +/- bevacizumab, in neoadjuvant, adjuvant and non-surgery linked treatment of recurrent glioblastoma: Phase I-II EOGBM1-18/ROSALIE study. (December 2022) - Wick, W.; IdBaih, A.; Vieito Villar, M.; Tabatabai, G.; Stradella, A.; Ghiringhelli, F.; Burger, M.; Mildenberger, I.; Herrlinger, U.; Touat, M.; Wen, P.; Wick, A.; et al.